Tested treatments for recurrent ovarian cancer with fluid buildup
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have recurrent ovarian, fallopian tube, or primary peritoneal cancer (certain cancer types/subtypes are allowed).
- You have symptomatic fluid around the belly and/or lungs that needs drainage at least once in the first 4 weeks, or you already have a drainage catheter.
- You feel well enough for treatment (ECOG performance status 0 to 1).
- You have not had pembrolizumab or any immune “checkpoint” cancer drug within the last 9 weeks.
- Your blood counts and organ tests are adequate (neutrophils, platelets, hemoglobin, kidney function, liver tests, and proteins must meet study thresholds).
- If you can become pregnant, you must have a negative pregnancy test and agree to 2 reliable birth-control methods (or abstain) during the study and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
Hear when a new Fallopian Tube Carcinosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.